Sanofi secures $43 million government funding for zika vaccine development
pharmafile | September 27, 2016 | News story | Manufacturing and Production, Research and Development | BARDA, Sanofi, Zika
The US Department of Health and Human Services approved $43.18 million to fund Sanofi’s development of a zika vaccine, the company has announced.
The firm’s vaccine unit, Sanofi Pasteur, voiced its intention to develop a vaccine in collaboration with the government in June. The funding comes from the BioMedical Advanced Research and Development Authority (BARDA) and runs until June 2022 and will be used to pursue mid-stage trials beginning in 2018; an additional $130.45 is contracted for later-stage trials in the event that the data generated is positive.
Takeda recently secured $312 million from the same authority to work on a zika vaccine and GSK has also gone on record with an interest to join the development race.
Matt Fellows
Related Content
Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia
Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib …
Sanofi shares phase 2b results for dermatitis treatment
Sanofi has shared positive results from part 2 of the investigational phase 2b STREAM-AD study …
Sanofi to acquire Inhibrx for approximately $1.7bn
Sanofi and Inhibrx, Inc have announced that they have entered into a definitive agreement for …